Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
Express Consolidation, Inc., et al.
BuyExclusive.Net (Gene Kim), U.S.
Royal Tronics, Inc. d/b/a MyCandyEyes.com, and Jamil Hindi, U.S.
MyCuteLens.com (Thy Xuan Ho a/k/a Brandon Lee), U.S.
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
BASF SE, a corporation, in the Matter of
BASF has settled Commission charges that its proposed $5.1 billion acquisition of rival chemical manufacturer Ciba Holding Inc. would be anticompetitive and violate federal law by reducing competition in the worldwide markets for two high performance pigments. Under the terms of a consent order allowing the transaction to proceed, the FTC requires BASF to sell all assets, including the intellectual property related to the two pigments, bismuth vanadate and indanthrone blue, to a Commission-approved buyer within six months.